SMO Antibody

說明書

中文名稱：

SMO兔多克隆抗體
貨號：

CSB-PA155823
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using CSB-PA155823(SMO Antibody) at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA155823(SMO Antibody) at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: ×200)
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

Q99835
基因名：

SMO
別名：

SMO; SMOH; Smoothened homolog; SMO; Protein Gx
宿主：

Rabbit
反應(yīng)種屬：

Human,Rat
免疫原：

Synthetic peptide of Human SMO
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:5000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點(diǎn)詳情

功能：

G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7, GLI2 and GLI3 in the cilia. Interacts with DLG5 at the ciliary base to induce the accumulation of KIF7 and GLI2 at the ciliary tip for GLI2 activation.
基因功能參考文獻(xiàn)：
1. Study present the crystal structure of the multi-domain human SMO in complex with a specially designed seven-transmembrane helices domain (TMD) ligand, shedding light on interactions between the cysteine-rich domain and TMD. Combining the structures with biophysical characterization and computer modelling results, study propose a mechanistic model of SMO activation. PMID: 28513578
2. Case Report: Happle-Tinschert Syndrome is caused by mosaic SMO mutations and represents a variant of Curry-Jones syndrome. PMID: 29335739
3. cholesterol within the bilayer is sufficient for constitutive Smoothened activation. Cholesterol effects occur independently of the lipid-binding Smoothened extracellular domain, a region that is dispensable for Patched1-Smoothened coupling. PMID: 29229834
4. A somatic mutation in SMO likely accounts for the structural malformations and predisposition to form bowel hamartomas and myofibromas. The mutation burden in the involved tissues likely accounts for the variable manifestations PMID: 28386950
5. Dual MET and SMO Inhibitors are potent antiproliferative agents in EGFR-Tyrosine kinase inhibitors resistant human non small cell lung cancer. PMID: 28787156
6. Smoothened-antagonists reverse alterations in Hedgehog signaling and chondrocyte primary cilium length in homogentisic acid induced model of alkaptonuria. PMID: 28019670
7. SMO mutation is associated with olfactory groove meningiomas. PMID: 28082415
8. SMO is covalently modified by cholesterol. This modification is regulated by Ptch1 and Hh and is essential for Hh signaling. PMID: 28344083
9. A screen for analogs revealed another six molecules, with IC50 values in the low micromolar range. Importantly, one of the most active of the new antagonists continued to be efficacious at the D473H mutant of Smoothened, which confers clinical resistance to the antagonist vismodegib in cancer treatment. PMID: 27490099
10. Our studies demonstrate an important role for smoothened and glioma-associated oncogene homology-1 in gastric cancer and suggest inhibition of hedgehog pathway as a novel and potent strategy to treat gastric cancer patients PMID: 28675107
11. The results suggest that Shh signaling plays an important role in rheumatoid arthritis-Fibroblast-like synoviocytes proliferation in a Smo-dependent manner. PMID: 26189371
12. Mutations in SMO gene is associated with Curry-Jones Syndrome. PMID: 27236920
13. The Hedgehog pathway receptor SMO is an important regulator of gastric cancer paclitaxel resistance. PMID: 28350784
14. Role of SMO-mediated Hedgehog signaling pathway in the proliferation and apoptosis of multiple myeloma cells PMID: 27959416
15. exogenous addition of 3beta,5alpha-dihydroxycholest-7-en-6-one, a naturally occurring B-ring oxysterol derived from 7-DHC that also accumulates in Smith-Lemli-Opitz syndrome, blocked Hedgehog signaling by inhibiting activation of the essential transduction component Smoothened, through a mechanism distinct from Smoothened modulation by other lipids. PMID: 27162362
16. High SMO expression is associated with pancreatic and skin cancers. PMID: 26784250
17. crystal structures of the Hh signal transducer and oncoprotein Smoothened, a GPCR that contains two distinct ligand-binding sites: one in its transmembrane domain and one in the cysteine-rich domain PMID: 27437577
18. Smoothened determines beta-arrestin-mediated removal of the G protein-coupled receptor Gpr161 from the primary cilium. PMID: 27002170
19. The combined inhibition of SMO and EGFR exerted a strong antiproliferative activity. PMID: 26124204
20. Suggest that hypoxia promotes SMO transcription through upregulation of MAML3 and RBPJ to induce proliferation, invasiveness and tumorigenesis in pancreatic cancer. PMID: 26655998
21. These findings suggest that miR-218 inhibits multidrug resistance of gastric cancer cells by down-regulating smoothened expression. PMID: 26261515
22. Recipient SMO rs3824 polymorphism is associated with an increased risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation. PMID: 25944162
23. Strikingly, in basal cell carcinoma patients treated with Smo inhibitor, squamous cell cancers with RAS/MAPK activation emerged from the antecedent basal cell carcinoma tumors. PMID: 26130651
24. report discussed two different SMO mutations representing examples of primary or secondary resistance respectively to vismodegib in two distinct basal cell carcinoma cases PMID: 25306392
25. The SMOF412E mutation was not detected in ameloblastoma. The BRAFV600E-activating mutation is a common event in ameloblastomas, occurring regardless of site or histological type. This mutation is also detected in odontogenic carcinomas. PMID: 25854168
26. SMO was upregulated in gliomas and was associated with tumor grade and survival period. SMO inhibition suppressed the biological behaviors of glioma cells. SMO expression was inversely correlated with miR-326 and is a novel direct target of miR-326. PMID: 25173582
27. SMO expression was significantly associated with better colorectal cancer-specific survival. PMID: 25023548
28. The Smoothened receptor (SMO) mediates signal transduction in the hedgehog pathway, which is implicated in normal development and carcinogenesis. PMID: 25008467
29. analysis of small-molecule regulation of SMO and discussion of potential mechanisms for its endogenous regulation [review] PMID: 25785427
30. SMO mutations are implicated in drug resistance in basal cell carcinoma. PMID: 25759019
31. Mutations within the SMO protein are implicated in drug resistance in basal cell carcinoma. PMID: 25759020
32. Studies indicate that Smoothened (Smo) inhibitor was beneficial for the treatment of advanced basal cell carcinoma (BCC). PMID: 24469022
33. signaling mediated by Smo contributes to acquired chemoresistance through activating the transcriptional factor Gli PMID: 24393163
34. SMO mutation is asociated with ameloblastoma. PMID: 24859340
35. MicroRNA-338-3p could inhibit colorectal carcinoma cell invasion and migration by inhibiting smoothened expression. PMID: 24277750
36. The structure of the Smo receptor will promote the development of small molecules interacting with a key therapeutic target with interests in regenerative medicine and cancer.[review] PMID: 24148123
37. miR-338-3p could suppress colorectal carcinoma growth by inhibiting SMO protein expression. PMID: 23599646
38. We observed strong correlation between higher SMO and SHH expression levels with poorer overall survival. PMID: 23379358
39. Smo antagonism led to reduced Hedgehog pathway activity, resulting in decreased cell proliferation and induction of apoptosis via the intrinsic pathway in the esophageal cancer cells PMID: 23915072
40. GSA-10 allows the pharmacological characterization of a novel Smo active site. PMID: 23448715
41. downregulation of miR-326 may be a possible mechanism for unrestricted activation of Smo signal transducer of the oncogenic Hedgehog pathway in chronic myeloid leukemia PMID: 23341351
42. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition PMID: 23508962
43. crystal structure of the transmembrane domain of the human SMO receptor bound to the small-molecule antagonist LY2940680 at 2.5 A resolution PMID: 23636324
44. A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways. PMID: 23334667
45. High SMO expression is asociated with postoperative liver metastasis in colon cancer. PMID: 23098507
46. SMO mutations, which activate Hedgehog signaling, were identified in ~5% of non-NF2 mutant meningiomas PMID: 23348505
47. High SMO expression is associated with colorectal cancer. PMID: 22901214
48. Study shows that hedgehog signaling rewires cellular metabolism; Smo-dependent noncanonical signal rewires metabolism in vitro and in vivo. PMID: 23063129
49. different pools of Smo move into cilia through distinct mechanisms PMID: 22864913
50. the effects of oxysterols on Hedgehog signaling are exquisitely stereoselective, consistent with the hypothesis that they function through a specific protein target. PMID: 22231273
顯示更多

收起更多
相關(guān)疾?。?/div>
Curry-Jones syndrome (CRJS)
亞細(xì)胞定位：

Membrane; Multi-pass membrane protein. Cell projection, cilium.
蛋白家族：

G-protein coupled receptor Fz/Smo family
數(shù)據(jù)庫鏈接：

HGNC: 11119

OMIM: 601500

KEGG: hsa:6608

STRING: 9606.ENSP00000249373

UniGene: Hs.437846

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human